STOCKHOLM, Nov. 3, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that six abstracts covering pozdeutinurad (AR882), nanoencapsulated sirolimus plus pegadricase (NASP) and uncontrolled gout will be presented at ACR Convergence 2026, the American College of Rheumatology annual meeting, taking place 6-11 November 2026 in Orlando, Florida. The presentations include results from the Phase 3 REDUCE-2 study of pozdeutinurad, analyses from the DISSOLVE I/II Phase 3 trials of NASP, and real-world and patient preference research on uncontrolled gout in the United States.

"Gout can have a substantial impact on the daily lives of those living with the condition, particularly when it remains uncontrolled or tophi develop," said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs and Chief Medical Officer at Sobi. "Through our clinical development programmes and patient-focused research, we aim to better understand these challenges and more effectively address patients' treatment needs."


        
          Oral presentation


                                                                                                          
 LB 20


        Treatment with URAT1 Inhibitor Pozdeutinurad (AR882) in a Phase 3, Double-Blind, Randomized
Study Lowers Serum Urate Levels in Participants with Gout                                                   Wednesday 11 November


                                                                                                            8:15 AM -8:30



        
          Poster presentations


                                                                                                                             1652


        Evaluation of DISSOLVE I/II Stopping Rules for Nanoencapsulated Sirolimus Plus Pegadricase
(NASP) in Patients with Uncontrolled Gout                                                                   Monday 9 November,


                                                                                                          
 10:30-12:30


                                                                                                                             1527


        Association Between Clinical Manifestations of Gout and Patient Reported Outcome Measures:
Results of a Real-World Survey in the United States                                                         Monday 9 November,


                                                                                                          
 10:30-12:30


                                                                                                                             2651


        Pooled Results from the Phase 3 Trials of Nanoencapsulated Sirolimus Plus Pegadricase in
Uncontrolled Gout: Characterization of Adverse Events of Special Interest                                   Tuesday 10 November,


                                                                                                          
 10:30-12:30


                                                                                                                             2531


        Patient Preferences for Uricase Treatments in Uncontrolled Gout in the United States: A Discrete
Choice Experiment                                                                                           Tuesday 10 November,


                                                                                                          
 10:30-12:30


                                                                                                                             2536


        The Impact of Tophi and Elevated Serum Urate (SU) Levels on Health-Related Quality of Life
(HRQoL) and Daily Functioning in Patients (pts) With Uncontrolled Gout (UG)                                 Tuesday 10 November,


                                                                                                          
 10:30-12:30

All times are local to Orlando

About gout

Gout is the most common form of systemic inflammatory arthritis¹. Elevated serum urate (SU) levels can lead to the accumulation of monosodium urate crystals in joints and other tissues, causing flares, joint damage and intense pain². Uncontrolled gout is a systemic, progressive disease characterised by SU levels above 6 mg/dL and persistent, debilitating clinical manifestations, including flares and/or tophi, despite treatment with oral urate-lowering therapies^3,4. Elevated SU levels have also been associated with cardiovascular, renal and metabolic diseases. Sustained serum urate (SU) lowering is central to gout management, promoting dissolution of monosodium urate crystals, limiting further crystal deposition, and reducing gout symptoms.

About pozdeutinurad

Pozdeutinurad (AR882) is an investigational once daily oral, highly selective URAT1 inhibitor being developed to treat uncontrolled gout. Phase 2 studies demonstrated clinically significant efficacy with a sustained reduction of serum urate (SU) levels, dissolution of tophi and a generally well-tolerated safety profile. Pozdeutinurad is being evaluated in more than 800 patients, two 12-month, randomised, double-blind, placebo-controlled Phase 3 studies, REDUCE 1 and REDUCE 2, assessing its ability to reduce SU in patients with uncontrolled gout.

About NASP (nanoencapsulated sirolimus plus pegadricase)

NASP is a novel, investigational medicine designed to reduce serum urate (SU) levels in people living with uncontrolled gout. NASP is administered every 4 weeks as a sequential, two-component, infusion therapy with a built-in immunomodulator, consisting of tolerogenic nanoencapsulated sirolimus (NAS) which mitigates the formation of anti-drug antibodies (ADAs) and a uricase, pegadricase (P), which reduces SU.

Sobi®

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

Contacts

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

¹FitzGerald JD. Gout. Annals of Internal Medicine. 2025;178(3):ITC33-ITC48. doi:10.7326/ANNALS-24-03951.
²Mayo Clinic. Gout - Symptoms and causes. Available at: https://www.mayoclinic.org/diseases-conditions/gout/symptoms-causes/syc-20372897.
³ Chen-Xu M, et al. Arthritis Rheumatol. 2019;71(6):991-999.
⁴McAdams MA, et al. J Rheumatol. 2011;38(1):135-141.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-to-present-new-gout-data-at-acr-convergence-2026,c4418705

The following files are available for download:


 
 https://mb.cision.com/Main/14266/4418705/4350827.pdf Sobi to present new gout data at ACR
                                                          Convergence 2026

View original content:https://www.prnewswire.co.uk/news-releases/sobi-to-present-new-gout-data-at-acr-convergence-2026-302927578.html

Tags

More Like This

Sobi showcases new data across rare inflammatory conditions at ACR 2025

FDA Accepts Biologics License Application for Sobi's NASP for Patients with Uncontrolled Gout

Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

Sobi to present New One-Year Data on pegcetacoplan's efficacy in C3G and primary IC-MPGN and new outcome data on NASP at ASN Kidney Week

Late-breaking Phase 3 REDUCE-2 data show clinically meaningful and durable serum urate lowering with pozdeutinurad

Invitation: Sobi's NASP and Uncontrolled Gout call and webcast

Sobi completes acquisition of Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout